Immunohistochemical Expression of “HE4” in Endometrial Hyperplasia versus Endometrial Endometrioid Carcinoma

Amany Talaat Abd El-Hamed; Samira Abd-Allah Mahmoud; Ahmed A. Soliman; Dina F. El-Yasergy

doi:10.3889/oamjms.2021.6189

Authors

Amany Talaat Abd El-Hamed Department of Pathology
Samira Abd-Allah Mahmoud Department of Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt
Ahmed A. Soliman Department of Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt
Dina F. El-Yasergy Department of Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt

DOI:

https://doi.org/10.3889/oamjms.2021.6189

Keywords:

Endometrial carcinoma, Endometrial hyperplasia, HE4, Immunohistochemistry

Abstract

Aim

Endometrial cancer is the most common cancer of the female genital tract. No effective biomarkers currently exist to allow for an efficient risk classification of endometrial carcinoma. Human epididymis protein 4 (HE4) overexpression is first observed in ovarian cancer tissue and subsequent research has shown that the HE4 overexpression has also been observed in patients with endometrial carcinoma. To our knowledge, this marker was evaluated in small number of research studies in cases of endometrial carcinoma versus hyperplasia. This has inspired us to test for immunohistochemical expression of HE4 in endometrial endometrioid carcinoma and hyperplastic endometria and to correlate HE4 expression with various prognostic pathological parameters including International Federation of Gynecology and Obstetrics (FIGO) grading and staging.

Methods

Immunohistochemical staining for HE4 was performed on paraffin-embedded sections of forty cases of endometrial endometrioid carcinoma and thirty cases of endometrial hyperplasia: including 15 cases of non-atypical hyperplasia and 15 cases of atypical hyperplasia. A histochemical score was used to evaluate HE4 expression by the tumor cells.

Results

In this study, HE4 overexpression level was significantly higher in endometrial endometrioid carcinoma than endometrial hyperplasia and significantly higher than non-atypical endometrial hyperplasia (P<0.05). HE4 strong expression was detected in 20% of atypical endometrial hyperplasia, but no statistical significance was detected between atypical hyperplasia and endometrial carcinoma. HE4 overexpression showed statistically significant positive correlation with FIGO grading, FIGO staging, and depth of myometrial invasion.

Conclusion:

During interpretation of endometrial biopsies of atypical hyperplasia, HE4 strong expression might raise the possibility of the presence of coexisting adenocarcinoma not biopsied or even warning of a near future malignant transformation. Also, strong expression of HE4 by tissue biopsy of adenocarcinoma should be reported as this might predict higher grade and stage of the tumor, a point that should be considered by surgeons while performing hysterectomy. These results should be further confirmed by extending the study on a large scale, correlation of HE4 expression with the molecular classification of Tumor Cancer Genome Atlas and long term follow up are required to establish the prognostic significance of HE4 expression in endometrial carcinoma and atypical hyperplasia.

Keywords: Endometrial carcinoma, Endometrial hyperplasia, HE4, Immunohistochemistry.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Brennan DJ, Hackethal A, Metcalf AM, Coward J, Ferguson K, Oehler MK, et al. Serum HE4 as a prognostic marker in endometrial cancer-a population based study. Gynecol Oncol. 2014;132(1):159-65. https://doi.org/10.1016/j.ygyno.2013.10.036 PMid:24211402 DOI: https://doi.org/10.1016/j.ygyno.2013.10.036

Doll A, Abal M, Rigau M, Monge M, Gonzalez M, Demajo S, et al. Novel molecular profiles of endometrial cancer-new light through old windows. Mol Biol. 2008;108(3-5):221-9. https://doi.org/10.1016/j.jsbmb.2007.09.020 PMid:18061438 DOI: https://doi.org/10.1016/j.jsbmb.2007.09.020

Jiang LN, Zhang HJ, Zhang HJ. The study of HE4, CA125 and CA72-4 for differential diagnosis between ovarian endometriosis and ovarian cancer. Chin J Lab Diagn. 2014;18(3):394-6.

Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: Correlation with pathological outcome. Gynecol Oncol. 2013;128(2):233-8. https://doi.org/10.1016/j.ygyno.2012.11.026 PMid:23200911 DOI: https://doi.org/10.1016/j.ygyno.2012.11.026

Schummer M, Ng WV, Bumgarner RE, Nelson PS, Schummer B, Bednarski DW, et al. Comparative hybridization of an array of 21, 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene. 1999;238(2):375-85. https://doi.org/10.1016/s0378-1119(99)00342-x PMid:1057096 DOI: https://doi.org/10.1016/S0378-1119(99)00342-X

Yu S, Yang HJ, Xie SQ, Bao YX. Diagnostic value of HE4 for ovarian cancer: A meta-analysis. Clin Chem Lab Med. 2012;50(8):1439-46. PMid:22868811 DOI: https://doi.org/10.1515/cclm-2011-0477

Karlsen NS, Karlsen MA, Hogdall CK, Hogdall EV. HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumors: A systematic review. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2285-95. https://doi.org/10.1158/1055-9965.epi-14-0447 PMid:25169975 DOI: https://doi.org/10.1158/1055-9965.EPI-14-0447

Galgano MT, Hampton GT, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19(6):847-53. https://doi.org/10.1038/modpathol.3800612 PMid:16607372 DOI: https://doi.org/10.1038/modpathol.3800612

Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2008;110(2):196-201. https://doi.org/10.1016/j.ygyno.2008.04.002 PMid:18495222 DOI: https://doi.org/10.1016/j.ygyno.2008.04.002

Deng L, Gao Y, Li X, Cai M, Wang H, Zhang H, et al. Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial cancer. J Exp Clin Cancer Res. 2015;34(1):96. https://doi.org/10.1186/s13046-015-0208-8 PMid:26362938 DOI: https://doi.org/10.1186/s13046-015-0208-8

Li J, Lin J, Luo Y, Kuang M, Liu Y. A multivariate analysis of prognostic biomarkers in surgically treated endometrial cancer. PLoS One. 2015;10(6):e0130640. https://doi.org/10.1371/journal.pone.0130640 PMid:26107255 DOI: https://doi.org/10.1371/journal.pone.0130640

Yang CH, Xu YH, Zhang XY. Expression and significance of human epididymis gene product 4 in tissue and serum of patients with endometrial cancer. Chin J Clin Oncol. 2011;38(9):516-9.

Lu R, Sun X, Xiao R, Zhou L, Gao X, Guo L. Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. Biochem Biophys Res Commun. 2012;419(2):274-80. https://doi.org/10.1016/j.bbrc.2012.02.008 PMid:22342977 DOI: https://doi.org/10.1016/j.bbrc.2012.02.008

Trudel D, Tetu B, Gregoire J, Plante M, Renaud MC, Bachvarov D, et al. Human epididymis protein 4 (HE4) and ovarian cancer prognosis. Gynecol Oncol. 2012;127(3):511-5. https://doi.org/10.1016/j.ygyno.2012.09.003 PMid:22967799 DOI: https://doi.org/10.1016/j.ygyno.2012.09.003

Zaino R, Carinelli SG, Ellenson LH. Epithelial tumors and precursors. In: Kurman RJ, editor. WHO Classification of Tumours of the Female Reproductive Organs. Lyon, France: IARC; 2014. p. 125-35.

Zhou Q, Singh SR, Yunzhe L, Mo Z, Huang J. Preoperative histopathological grading and clinical staging versus surgico-pathological grading and surgical staging in endometrial carcinoma patients: A single centre retrospective study. Glob J Med Res. 2018;18:18-28.

FIGO Committee on Gynecologic Oncology. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int J Gynaecol Obstet. 2014;125(2):97-8. https://doi.org/10.1016/j.ijgo.2014.02.003 PMid:24630859 DOI: https://doi.org/10.1016/j.ijgo.2014.02.003

Powéll MA, Olawaiye AB, Bermudez A. Corpus uteri-carcinoma and carcinosarcoma. In: Amin MB, Edge SB, Greene FL, editors. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017. p. 639-57.

Kommoss F, Grevenkamp F, Bunz AK, Taran FA, Fend F, Lax S. L1CAM: Amending the low-risk category in endometrial carcinoma. J Cancer Res Clin Oncol. 2017;143(2):255-62. https://doi.org/10.1007/s00432-016-2276-3 PMid:27695947 DOI: https://doi.org/10.1007/s00432-016-2276-3

Kumarasamy C, Madhav MR, Sabarimurugan S, Lakhotiya K, Pandey V, Priyadharshini T, et al. Diagnostic and prognostic role of HE4 expression in multiple carcinomas: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2019;98(28):e15336. https://doi.org/10.1097/md.0000000000015336 PMid:31305389 DOI: https://doi.org/10.1097/MD.0000000000015336

Khatuja R, Rai S. Endometrial carcinoma: Epidemiology and risk factors. In: Preventive Oncology for the Gynecologist. Singapore: Springer; 2019. p. 3-12. https://doi.org/10.1007/978-981-13-3438-2_1 DOI: https://doi.org/10.1007/978-981-13-3438-2_1

Helal EA, Salman MI, Ezz-Elarab SS. Malignant tumors of the body of uterus. In: Pathology-Based Cancer Registry 2002- 2010. 1st ed. Cairo, Egypt: Ain-Shams Faculty of Medicine; 2015. p. 54-56.

Zhang Z, Chen HX, Xu XX. The values of the combined detection of serum human epididymis protein E4, CA125 and CA199 in diagnosis of endometrial cancer. J Pract Med. 2016;32(7):1108-12.

Mutz-Dehbalaie I, Egle D, Fessler S, Hubalek M, Fiegl H, Marth C, et al. HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol. 2012;126(2):186-91. https://doi.org/10.1016/j.ygyno.2012.04.022 PMid:22525819 DOI: https://doi.org/10.1016/j.ygyno.2012.04.022

Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer. 2011;104(9):1418-25. https://doi.org/10.1038/bjc.2011.109 PMid:21468050 DOI: https://doi.org/10.1038/bjc.2011.109

Moore RG, Miller MC, Disilvestro P, Landrum LM, Gajewski W, Ball JJ, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol. 2011;118(2):280-8. https://doi.org/10.1097/aog.0b013e318224fce2 DOI: https://doi.org/10.1097/AOG.0b013e318224fce2

Li J, Chen H, Mariani A, Chen D, Klatt E, Podratz K, et al. HE4 (WFDC2) promotes tumor growth in endometrial cancer cell lines. Int J Mol Sci. 2013;14(3):6026-43. https://doi.org/10.3390/ijms14036026 PMid:23502467 DOI: https://doi.org/10.3390/ijms14036026